Try
BridgeBio Pharma Inc.
BBIOUnited States
37 filed reports · 610 financial concepts · 2 earnings calls · 0 media appearances
Filed reports
37 reports · Jun 2019 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 134 commentary passages.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 28 | 4,632 | Jun 2019 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 9 | 3,831 | Dec 2019 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 10, 2026 | 529 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 1 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 325 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 1 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 1,202 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 29, 2025 | 400 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 29, 2025 | 1 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 1 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 320 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | Apr 29, 2025 | 277 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | Apr 29, 2025 | 1 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 20, 2025 | 3 | Open |
Financial data
610 concepts · 8,463 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial584 concepts · 7,925 facts · Mar 2017 to Jun 2026
- Money Market Funds45 · Dec 2021 to Jun 2026
- Stockholders equity including portion attributable to noncontrolling interest44 · Dec 2017 to Jun 2026
- Accumulated Deficit43 · Dec 2017 to Jun 2026
- Minority interest period increase decrease43 · Dec 2017 to Jun 2026
- Cash and cash equivalents at carrying value42 · Dec 2017 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations42 · Dec 2017 to Jun 2026
- Allocated share based compensation expense41 · Dec 2017 to Jun 2026
- Common stock value41 · Dec 2017 to Jun 2026
- Comprehensive income net of tax41 · Dec 2017 to Jun 2026
- Investment income interest41 · Dec 2017 to Jun 2026
- Minority interest41 · Dec 2017 to Jun 2026
- Net income loss attributable to noncontrolling interest41 · Dec 2017 to Jun 2026
- Net income loss available to common stockholders basic41 · Dec 2017 to Jun 2026
- Nonoperating income expense41 · Dec 2017 to Jun 2026
- Operating income loss41 · Dec 2017 to Jun 2026
- Profit loss41 · Dec 2017 to Jun 2026
- Research and development expense41 · Dec 2017 to Jun 2026
- Retained earnings accumulated deficit41 · Dec 2017 to Jun 2026
- Stockholders equity (US GAAP)41 · Dec 2017 to Jun 2026
- Accrued research and development liabilities40 · Dec 2017 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect40 · Dec 2017 to Jun 2026
- Increase decrease in accounts payable40 · Dec 2017 to Jun 2026
- Increase decrease in employee related liabilities40 · Dec 2017 to Jun 2026
- Increase decrease in other operating assets40 · Dec 2017 to Jun 2026
Segment22 concepts · 413 facts · Dec 2022 to Jun 2026
- Revenue61 · Dec 2022 to Jun 2026
- Cost of revenue (US GAAP)48 · Dec 2022 to Jun 2026
- Costs and expenses18 · Dec 2022 to Jun 2026
- Gains losses on extinguishment of debt18 · Dec 2022 to Jun 2026
- Income loss from equity method investments18 · Dec 2022 to Jun 2026
- Interest expense nonoperating18 · Dec 2022 to Jun 2026
- Investment income interest18 · Dec 2022 to Jun 2026
- Net income loss attributable to noncontrolling interest18 · Dec 2022 to Jun 2026
- Net income loss available to common stockholders basic18 · Dec 2022 to Jun 2026
- Nonoperating income expense18 · Dec 2022 to Jun 2026
- Operating income loss18 · Dec 2022 to Jun 2026
- Other nonoperating income expense18 · Dec 2022 to Jun 2026
- Profit loss18 · Dec 2022 to Jun 2026
- Research and development expense18 · Dec 2022 to Jun 2026
- Selling general and administrative expense18 · Dec 2022 to Jun 2026
- Restructuring settlement and impairment provisions15 · Dec 2023 to Jun 2026
- Income tax expense benefit14 · Dec 2022 to Jun 2026
- Deconsolidation gain or loss amount12 · Dec 2022 to Dec 2025
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest12 · Dec 2022 to Jun 2026
- Noncash interest expense on deferred royalty obligations11 · Dec 2023 to Jun 2026
- Gain from sale of priority review voucher, net3 · Dec 2022 to Dec 2024
- Restructuring charges3 · Dec 2022 to Dec 2024
Product3 concepts · 117 facts · Dec 2019 to Jun 2026
- Revenue78 · Dec 2019 to Jun 2026
- Cost of revenue (US GAAP)30 · Dec 2023 to Jun 2026
- Revenue (excluding assessed tax)9 · Dec 2019 to Dec 2024
Geography1 concepts · 8 facts · Dec 2021 to Dec 2024
- United States8 · Dec 2021 to Dec 2024
Segments
538 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments2 members · 413 facts
- Reportable265 · Dec 2023 to Jun 2026
- Reportable Segment Aggregation Before Other Operating148 · Dec 2022 to Jun 2025
Product or service13 members · 117 facts
- Product34 · Sep 2020 to Jun 2026
- License And Service22 · Dec 2020 to Jun 2026
- License Services And Royalty11 · Dec 2023 to Jun 2026
- Royalty11 · Dec 2023 to Jun 2026
- License10 · Dec 2019 to Mar 2022
- License9 · Dec 2019 to Dec 2024
- Cost Of Goods Sold4 · Mar 2024 to Jun 2025
- License And Services Revenue4 · Mar 2024 to Jun 2025
- Net Product Revenue4 · Mar 2024 to Jun 2025
- Attruby2 · Jun 2025 to Sep 2025
- Cost Of License And Services Revenue2 · Mar 2024 to Mar 2025
- Cost Of License Services And Royalty Revenue2 · Jun 2024 to Jun 2025
- Royalty Revenue2 · Jun 2024 to Jun 2025
Statement geographical2 members · 8 facts
- CA4 · Dec 2021 to Dec 2024
- US4 · Dec 2021 to Dec 2024
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary150 claims from 10 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary134 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes23 claims from 1 reports · Dec 2025
- Risk factors205 risks from 2 annual reports · 2024 to 2025
Earnings calls
2 calls · May 2026 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 10, 2026
- FY2026 Q1May 7, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.